Sequoia Financial Advisors’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Sequoia Financial Advisors’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-156,000	Closed	-$102K	–	1481
2024 Q4	$102K	Buy	156,000 +87,000	+126%	+$35.5K	﹤0.01%	1283
2024 Q3	$26.1K	Buy	69,000 +50,500	+273%	+$44.8K	﹤0.01%	1276
2024 Q2	$23.5K	Buy	18,500 +2,500	+16%	+$3.49K	﹤0.01%	1211
2024 Q1	$30.2K	Buy	+16,000	New	+$30.7K	﹤0.01%	1150

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Sequoia Financial Advisors's NKGN Position: Q1 2025 in Review

Sequoia Financial Advisors sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 156,000 shares — an estimated $102K sold.

Sequoia Financial Advisors first reported a position in NKGN in Q1 2024 and held it in 4 quarters. The position peaked at $102K in Q4 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

Sequoia Financial Advisors reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Sequoia Financial Advisors sold 156,000 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $102K.
Sequoia Financial Advisors first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2024 and held it in 4 quarters.
Sequoia Financial Advisors's NKGen Biotech, Inc. Common Stock position peaked at $102K in Q4 2024.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Sequoia Financial Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.